Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
University of Michigan
Start Date
August 6, 2024
End Date
July 31, 2029
Administered By
Duke Cancer Institute
Awarded By
University of Michigan
Start Date
August 6, 2024
End Date
July 31, 2029